Partial Inhibition of Platelet Thromboxane A2 Synthesis by Aspirin Is Associated With Myonecrosis in Patients With ST-Segment Elevation Myocardial Infarction

American Journal of Cardiology

Volumn 99, Issue 1, 2007, Pages 19-25

  Valles, Juana ^a   Santos, M Teresa ^a   Fuset, M Paz ^a   Moscardo, Antonio ^a   Ruano, Miguel ^a   Perez, Francisca ^a   Piñon, Marta ^a   Breña, Silvia ^a   Aznar, Justo ^a  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CALCIUM CHANNEL BLOCKING AGENT; COLLAGEN; CREATINE KINASE; CREATINE KINASE MB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENOXAPARIN; FIBRINOLYTIC AGENT; GLYCERYL TRINITRATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRATE; THROMBOXANE A2; TROPONIN T;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; ENZYME INHIBITION; FEMALE; HEART INFARCTION; HEART MUSCLE INJURY; HUMAN; MAJOR CLINICAL STUDY; MALE; MUSCLE NECROSIS; PRIORITY JOURNAL; PROTEIN SYNTHESIS; REGULATORY MECHANISM; SINGLE DRUG DOSE; ST SEGMENT ELEVATION; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE KINETICS; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ASPIRIN; BLOOD PLATELETS; CASE-CONTROL STUDIES; DRUG RESISTANCE; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIUM; NECROSIS; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; SEVERITY OF ILLNESS INDEX; THROMBOXANE A2;

EID: 33845703949     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2006.07.058     Document Type: Article

References (29)

1. Helgason C.M., Bolin K.M., Hoff J.A., Winkler S.R., Mangat A., Tortorice K.L., and Brace L.D. Development of aspirin resistance in persons with previous ischemic stroke. Stroke 25 (1994) 2331-2336
2. Valles J., Santos M.T., Aznar J., Osa A., Lago A., Cosin J., Sanchez E., Broekman M.J., and Marcus A.J. Erythrocyte promotion of platelet reactivity decreases the effectiveness of aspirin as an antithrombotic therapeutic modality: the effect of low-dose aspirin is less than optimal in patients with vascular disease due to prothrombotic effects of erythrocytes on platelet reactivity. Circulation 97 (1998) 350-355
3. Gum P.A., Kottke-Marchant K., Poggio E.D., Gurm H., Welsh P.A., Brooks L., Sapp S.K., and Topol E.J. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 88 (2001) 230-235
4. Grotemeyer K.H., Scharafinski H.W., and Husstedt I.W. Two-year follow-up of aspirin responder and aspirin non-responder. A pilot-study including 180 post-stroke patients. Thromb Res 71 (1993) 397-403
5. Mueller M.R., Salat A., Stangl P., Murabito M., Pulaki S., Boehm D., Koppensteiner R., Ergun E., Mittlboeck M., Schreiner W., et al. Variable platelet response to low-dose ASA and the risk of limb deterioration in patients submitted to peripheral arterial angioplasty. Thromb Haemostas 78 (1997) 1003-1007
6. Chamorro A., Escolar G., Revilla M., Obach V., Vila N., Reverter J.C., and Ordinas A. Ex vivo response to aspirin differs in stroke patients with single or recurrent events: a pilot study. J Neurol Sci 171 (1999) 110-114
7. Gum P.A., Kottke-Marchant K., Welsh P.A., White J., and Topol E.J. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 41 (2003) 961-965
8. Eikelboom J.W., Hirsh J., Weitz J.I., Johnston M., Yi Q., and Yusuf S. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 105 (2002) 1650-1655
9. Patrono C., Coller B., FitzGerald G.A., Hirsh J., and Roth G. Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 suppl 3 (2004) 234S-264S
10. Topol E.J., and Quinn M.J. Common variations in platelet glycoproteins: pharmacogenomic implications. Pharmacogenomics 2 (2001) 341-352
11. Schafer A.I. Genetic and acquired determinants of individual variability of response to antiplatelet drugs. Circulation 108 (2003) 910-911
12. Eikelboom J.W., and Hankey G.J. Aspirin resistance: a new independent predictor of vascular events?. J Am Coll Cardiol 41 (2003) 966-968
13. Santos M.T., Valles J., Marcus A.J., Safier L.B., Broekman M.J., Islam N., Ullman H.L., Eiroa A.M., and Aznar J. Enhancement of platelet reactivity and modulation of eicosanoid production by intact erythrocytes. J Clin Invest 87 (1991) 571-580
14. Valles J., Santos M.T., Aznar J., Marcus A.J., Martinez-Sales V., Portoles M., Broekman M.J., and Safier L.B. Erythrocytes metabolically enhance collagen-induced platelet responsiveness via increased thromboxane production, ADP release, and recruitment. Blood 78 (1991) 154-162
15. Santos M.T., Valles J., Aznar J., Marcus A.J., Broekman M.J., and Safier L.B. Prothrombotic effects of erythrocytes on platelet reactivity: reduction by aspirin. Circulation 95 (1997) 63-68
16. Alpert J.S., Thygesen K., Antman E., and Bassand J.P. Myocardial infarction redefined. A consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol 36 (2000) 959-962
17. Antman E.M. Troponin measurements in ischemic heart disease: more than just a black and white picture. J Am Coll Cardiol 38 (2001) 987-990
18. 3 integrin receptor activation and aspirin-insensitive mechanisms of thrombin-stimulated human platelets. Circulation 102 (2000) 1924-1930
19. 3 integrin receptor activation and P-selectin expression during platelet recruitment: downregulation by aspirin ex vivo. Blood 99 (2002) 3978-3984
20. Fitzgerald D.J., Catella F., Roy L., and FitzGerald G.A. Marked platelet activation in vivo after intravenous streptokinase in patients with acute myocardial infarction. Circulation 77 (1988) 142-150
21. Rasmanis G., Vesterqvist O., Green K., Edhag O., and Henriksson P. Evidence of increased platelet activation after thrombolysis in patients with acute myocardial infarction. Br Heart J 68 (1992) 374-376
22. Rocca B., Secchiero P., Ciabattoni G., Ranelletti F.O., Catani L., Guidotti L., Melloni E., Maggiano N., Zauli G., and Patrono C. Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets. Proc Natl Acad Sci USA 99 (2002) 7634-7639
23. 2 as an amplifying signal for other agonists. Am J Cardiol 68 suppl (1991) 11B-15B
24. 2 receptors in patients with acute myocardial infarction. Circulation 81 (1990) 212-218
25. Maree A.O., Curtin R.J., Chubb A., Dolan C., Cox D., O'Brien J., Crean P., Shields D.C., and Fitzgerald D.J. Cyclooxygenase-1 haplotype modulates platelet response to aspirin. J Thromb Haemost 3 (2005) 2340-2345
26. Lepantalo A., Mikkelsson J., Resendiz J.C., Viiri L., Backman J.T., Kankuri E., Karhunen P.J., and Lassila R. Polymorphisms of COX-1 and GPVI associate with the antiplatelet effect of aspirin in coronary artery disease patients. Thromb Haemost 95 (2006) 253-259
27. Evangelista V., Manarini S., Di Santo A., Capone M.L., Ricciotti E., Di Francesco L., Tacconelli S., Sacchetti A., D'Angelo S., Scilimati A., et al. De novo synthesis of cyclooxygenase-1 counteracts the suppression of platelet thromboxane biosynthesis by aspirin. Circ Res 98 (2006) 593-595
28. Frossard M., Fuchs I., Leitner J.M., Hsieh K., Vlcek M., Losert H., Domanovits H., Schreiber W., Laggner A.N., and Jilma B. Platelet function predicts myocardial damage in patients with acute myocardial infarction. Circulation 110 (2004) 1392-1397
29. Chen W.-H., Lee P.-Y., Ng W., Tse H.-F., and Lau C.-P. Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment. J Am Coll Cardiol 43 (2004) 1122-1126